A PHASE II OPEN-LABEL, SINGLE CENTER TRIAL OF ORAL DECITABINE-CEDAZURIDINE (INQOVI®) IN COMBINATION WITH THIOGUANINE (TABLOID®) IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Contact:

212-342-5162

NCT Number:

NCT06351306

Protocol:

AAAU5915

Study Status:

Active/Enrolling

Population:

Adult

Phase:

II

You are being asked to participate in this study because you have acute myeloid leukemia (AML) whose disease has returned or did not respond to treatment (relapsed or refractory). The purpose of the study is to see how safe and effective the combination of decitabine- cedazuridine and thioguanine is in treating your cancer.

Are you Eligible? (Inclusion Criteria)

  • At least 18 years of age or older 2. Are you able to give written informed consent and be able to comply with all study requirements? 3. Subjects must have adequate organ function

Specialty Area(s)

Leukemia, Acute Myeloid Leukemia

Principal Investigator

Joseph G. Jurcic, MD

Profile Headshot
  • Director, Hematologic Malignancies Section